February 3, 2014 / 4:38 PM / in 4 years

CORRECTED-MARKET PULSE-AOL, Ford Motor, Pfizer, Oramed Pharma, Kratos Defense

(Corrects Galena Biopharma item to clarify that the analyst did not comment on the blog’s claim that the drug “has killed plenty of people”) U.S. stocks were down on Monday, adding to recent losses after data showed the factory sector in the world’s largest economy expanded in January at its slowest pace in eight months. The Dow Jones industrial average was down 1.14 percent at 15,519.96, the S&P 500 was down 1.19 percent at 1,761.34 and the Nasdaq Composite was down 1.38 percent at 4,047.256.

** AT&T INC, $32.34, -2.94 pct

** T-MOBILE US INC, $30.49, -0.26 pct

** VERIZON COMMUNICATIONS INC, $46.689, -2.77 pct

AT&T’s plan to cut prices on its large shared data plans is aimed at winning customers in an increasingly fierce competition with rivals such as T-Mobile US and could force larger rival Verizon to offer new discounts, analysts said.

** JOS. A. BANK CLOTHIERS INC, $54.08, -3.81 pct

** MEN‘S WEARHOUSE INC, $44.66, -7.04 pct

Jos. A. Bank rejected on Sunday yet another offer by rival Men’s Wearhouse, the latest in a prolonged acquisition battle between the two men’s clothing retailers.

Jos. A. Bank was said to be in talks buy retailer Eddie Bauer Inc from private equity owner Golden Gate Capital, said a source familiar with the talks on Saturday.

** FORD MOTOR CO, $14.57, -2.61 pct

** GENERAL MOTORS CO, $35.52, -1.55 pct

The U.S. automakers saw their January auto sales plummet, missing analysts’ estimates for the month. But early sales results were mixed for other companies and brands, with Chrysler Group, a unit of Fiat Chrysler Automobiles, and Nissan North America reporting increases and topping analysts’ estimates, while Toyota Motor Sales USA missed on a year-to-year decline.

GM, Ford and Toyota, the top three U.S. sellers, all blamed bad weather for poor performances.

** PFIZER INC, $31.32, +3.03 pct

The drugmaker’s experimental breast cancer drug significantly improved patient survival rates in a mid-stage trial without their condition worsening, maintaining the company’s lead in the race for a new treatment standard for the disease.


The Canada-based company agreed to acquire privately held PreCision Dermatology Inc for $475 million in cash to strengthen its skin products business.

** BIOTELEMETRY INC, $8.91, +22.22 pct

The wireless medical technology company said Mednet Healthcare Technologies and its units entered into a consent judgment stating that they infringed on five patents owned by BioTelemetry, which are all valid.

BioTelemetry said it bought all outstanding shares of Mednet, which makes cardiac monitoring devices, for $16 million. The purchase price comprises $5.5 million in cash, $800,000 of BioTelemetry’s common stock and the assumption of $9.7 million of debt.

** ORAMED PHARMACEUTICALS INC, $17.3844, -21.30 pct

A report from a noted biotechnology blogger on investment website TheStreet.com said clinical data released by the company on Thursday for its oral insulin pill was “completely worthless,” and questioned the pill’s safety and efficacy.

Oramed announced its insulin pill was "safe and well tolerated" in the mid-stage study without providing any statistics to support that claim, columnist Adam Feuerstein said in the report. (r.reuters.com/fat56v)

Oramed said on Thursday that its insulin capsule met the main and secondary goals of the study.

** INFOSONICS CORP, $2.7799, +19.31 pct

The electronics distributor launched KolorPadTM, a 7-inch tablet powered by Android 4.2 operating system priced at $149.


The defense contractor said it won a five-year contract worth up to $7.92 billion from the U.S. Navy.

** AOL INC, $47.95, +4.06 pct

Needham & Co raised its price target on the media company’s stock to $57 from $46, citing the “excess returns” generated by its mobile-first strategy.

“The strategic choices that AOL is making are first-rate, in our view, as is their execution track record of slowing the demise of subscription revenue (AOL’s key funding source),” analyst Laura Martin wrote in a note.

** GALENA BIOPHARMA INC, $4.35, -17.46 pct

The drugmaker’s shares fell after a blog post blamed the company for giving away a free month’s supply of its opioid pain drug, Abstral, said Maxim Group analyst Echo He.

"This ambitious marketing strategy allows more than enough time and supply to create addicts," blogger John Hempton wrote. (link.reuters.com/tat56v)

Galena's voucher posted on its website offers patients a maximum of 96 tablets of the drug for free in the first month and up to $500 off each prescription after the first month. (link.reuters.com/qat56v)


Needham & Co analyst Chad Messer raised his rating on the company’s stock to “buy” from “hold,” saying that positive data from mid-stage studies of its cancer drug and imaging agent validated its strategy of focusing on cancer.

Messer said that data showed the imaging agent to be more effective than magnetic resonance imaging scans in identifying the spread of prostate cancer, and the agent could progress quickly into late-stage studies.


The Canada-based drugmaker said it received milestone payments of about $3.1 million, relating to sales of its generic drug for attention deficit hyperactivity disorder by its licensee Par Pharmaceutical Inc.

** THERMOGENESIS CORP, $2.45, +11.36 pct

The company said its technology for stem cell recovery and isolation were used in the 20th pediatric bone marrow transplant conducted by India-based Fortis Healthcare, in partnership with TotipotentRx Corp, a privately-held cellular therapy research company.

ThermoGenesis and TotipotentRX entered into a merger agreement in July, which is subject to stockholder approval.

** UNITED ONLINE INC, $11.07, -8.59 pct

The online floral and gift service provider said on Friday that it would discontinue paying cash dividends in order to provide financial flexibility to support its long-term growth initiatives.

** LEUCADIA NATIONAL CORP, $26.1, -4.50 pct

A beef packing unit of the company said on Friday that it planned to close its Brawley, California beef processing plant with the final day of operation on April 4, due to dwindling cattle supplies.


The Sao Paulo water company announced big discounts on bills for consumers who reduce usage during the current drought.


The chipmaker said in a filing on Friday that its founder Martin William had bought about 2 million of its shares last week.

** JOURNAL COMMUNICATIONS, $8.34, +4.64 pct

Activist investor Mario Gabelli said if the newspaper and television station owner spins off its newspaper assets, its total assets could be worth $13-$15 per share, Barron's reported on Saturday. (link.reuters.com/pat56v)

Gabelli, Journal’s largest shareholder, has been raising his stake in the company.

** FIREEYE INC, $67.07, -8.11 pct

The cybersecurity provider and some of its shareholders plan to offer up to $700 million in common stock.

** CHARTER COMMUNICATIONS INC, $137.83, +0.61 pct

** TIME WARNER CABLE INC, $134.84, +1.18 pct

Charter Communications is discussing raising its bid for Time Warner Cable as soon as in the next two weeks, according to people familiar with the matter, a move that could pressure its reluctant rival ahead of a proxy deadline.

** MEDIVATION INC, $75.6, -5.03 pct

At least two brokerages, including Needham & Co and Bernstein, cut their ratings on the drugmaker’s stock.

Needham & Co analyst Chad Messer downgraded the stock to “hold” from “buy,” saying that the company could face hurdles during the development of its prostrate cancer drug, Xtandi, for wider use in patients who had not received chemotherapy.

Messer also said that Medivation’s drug could face competition from similar drugs being developed by Johnson & Johnson and privately-held companies including Tokai Pharmaceuticals and Viamet Pharmaceuticals Holdings LLC.

Bernstein downgraded the stock to “market-perform” from “outperform”, according to Streetinsider.com.

** RANDGOLD RESOURCES LTD, $72.87, +5.76 pct

The miner said it was looking to partner with smaller rivals weakened by lower gold prices and would continue to spend on exploration this year, as it posted record production for 2013.

** RYANAIR, $49.32, +4.38 pct

The Ireland-based company reported strong forward bookings and an easing of intense price competition among European airlines, raising hopes it can quickly regain height with a new customer-friendly image after a profit warning spooked markets last year.

** ARTHROCARE CORP, $48.56, +7.01 pct

Britain’s Smith & Nephew is to buy ArthroCare for an agreed $1.7 billion in cash to strengthen its treatments for sporting injuries, an area growing faster than its main replacement hips and knees business.

** LHC GROUP INC, $23.71, +3.36 pct

** BIOSCRIP INC, $8.7, +2.23 pct

Home healthcare and hospice services provider LHC Group said it would buy BioScrip’s home health business for $60 million in cash, expanding its business to 33 locations in five states.

LHC said the deal, which is expected to close by the end of the first quarter, would add $0.05-$0.10 per share to its earnings in 2014.

BioScrip said the deal would add to its earnings in 2014. (Compiled by Natalie Grover in Bangalore; Editing by Kirti Pandey)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below